From this view, the ongoing-research is now being pointing out as a striking target for cancer therapy by regaining p53 activity through interfering in the interaction of p53-mortalin complex, as, for example: by its antisense RNA, ribozymes, siRNA or a chemical targeting mortalin-p53 interaction such as MKT-077 (a cationic rhodacyanine dye) [41],[42],[54]. This evidence concerns the gene HSPA9 and cancer.